Immunome Inc. Files 8-K on Operations and Financials
Ticker: IMNM · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
Immunome Inc. dropped an 8-K on March 28th detailing financials and operations.
AI Summary
Immunome, Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Bothell, WA.
Why It Matters
This 8-K filing provides an update on Immunome Inc.'s financial health and operational status, which is crucial information for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Immunome, Inc. (company) — Registrant
- March 28, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Bothell, WA (location) — Address of principal executive offices
- 001-39580 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing for Immunome, Inc.?
The primary purpose is to report on Immunome, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on March 28, 2024.
In which state is Immunome, Inc. incorporated?
Immunome, Inc. is incorporated in Delaware.
What is the address of Immunome, Inc.'s principal executive offices?
The address is 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011.
What is Immunome, Inc.'s telephone number?
Immunome, Inc.'s telephone number is (610) 321-3700.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-28 16:04:40
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
Filing Documents
- tm2410047d1_8k.htm (8-K) — 29KB
- tm2410047d1_ex99-1.htm (EX-99.1) — 64KB
- 0001104659-24-040503.txt ( ) — 312KB
- immu-20240328.xsd (EX-101.SCH) — 3KB
- immu-20240328_def.xml (EX-101.DEF) — 26KB
- immu-20240328_lab.xml (EX-101.LAB) — 35KB
- immu-20240328_pre.xml (EX-101.PRE) — 24KB
- tm2410047d1_8k_htm.xml (XML) — 5KB
02 Results
Item 2.02 Results of Operations and Financial Condition. On March 28, 2024, Immunome, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
01 Financial Statements and
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated March 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 28, 2024 Immunome, Inc. By: /s/ Clay Siegall Name: Clay Siegall, Ph.D. Title: President and Chief Executive Officer